NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
138 trialsNCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT01316250 2025-10-02
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
Phase NA Completed
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01085617 2025-03-30
UKALL14
University College, London
Completed
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT06038552 2025-02-26
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT06628739 2024-10-08
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT02260505 2024-01-05
ImadGist
Centre Leon Berard
Phase 3 Completed
NCT04006769 2023-10-18
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Completed
NCT00161213 2023-08-14
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT00287105 2023-05-24
ESPHALL
Rennes University Hospital
Phase 2 Completed
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT03609424 2023-01-03
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Phase 1/2 Completed
NCT01475110 2022-10-25
CML0609
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT04883125 2021-05-12
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Mansoura University
Phase 2 Completed
NCT02303899 2021-01-22
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT00301093 2020-10-28
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00137111 2020-09-11
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00390156 2020-07-28
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT03131999 2020-06-16
LAMP-1
Medical University of South Carolina
Phase 1/2 Completed
NCT00219739 2020-04-13
SPIRIT
Poitiers University Hospital
Phase 3 Completed
NCT02257541 2020-03-30
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00509093 2020-03-17
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00338728 2020-01-27
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01151852 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Phase 3 Completed
NCT02495519 2020-01-14
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Yonsei University
Phase 2 Completed
NCT01578213 2019-12-03
ISAV
University of Milano Bicocca
Phase 4 Completed
NCT00049127 2019-10-21
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00632255 2019-07-08
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Imperial College London
Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00045669 2019-02-15
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00047502 2018-11-07
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00027586 2018-10-31
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038194 2018-10-31
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00401024 2018-06-28
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00055874 2018-05-03
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Heidelberg University
Phase 3 Completed
NCT00080665 2018-04-24
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed